Listar por autor "Maldonado-Sánchez, Rafael"
Mostrando ítems 1-4 de 4
-
Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients
García-León, Juan Antonio
; Pinto-Medel, Mª Jesús; García-Trujillo, Lucía; López-Gómez, Carlos; Oliver-Martos, Begoña; Prat-Arrojo, Isidro; Marín-Bañasco, Carmen; Suardíaz-García, Margarita; Maldonado-Sánchez, Rafael; Fernández Fernández, Óscar; Leyva-Fernández, Laura[et al.] (Elsevier, 2011)
Killer cell immunoglobulin-like receptors (KIRs) are regulators of cytolytic activity of natural killer and certain T cells through interactions with human leukocyte antigen (HLA) class I ligands. KIRs have been shown to ... -
Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients.
García-León, Juan Antonio; Pinto-Medel, María-Jesús; García-Trujillo, Lucía; López-Gómez, Carlos; Oliver-Martos, Begoña; Prat-Arrojo, Isidro; Marín-Bañasco, Carmen; Suardíaz-García, Margarita; Maldonado-Sánchez, Rafael; Fernández-Fernández, Óscar; Leyva-Fernández, Laura[et al.] (Elsevier, 2011-09)
Killer cell immunoglobulin-like receptors (KIRs) are regulators of cytolytic activity of natural killer and certain T cells through interactions with human leukocyte antigen (HLA) class I ligands. KIRs have been shown to ... -
Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months
Oliver-Martos, Begoña; Fernández Fernández, Óscar; Órpez, Teresa; Alvarenga, Marcos Papais; Pinto-Medel, Mª Jesús; Guerrero, Miguel; León, Antonio; López-Madrona, José Carlos; Maldonado-Sánchez, Rafael; García-León, Juan Antonio; Luque, Gloria; Fernández Sánchez, Victoria Eugenia; Leyva-Fernández, Laura[et al.] (SAGE Journals, 2011)
Natalizumab is a monoclonal antibody shown to be highly effective in the treatment of relapsing–remitting multiple sclerosis (RRMS). Patients treated with natalizumab can develop antibodies directed against this agent that ... -
Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.
Oliver-Martos, Begoña; Fernández, Óscar; Orpez, Teresa; Alvarenga, Marco Papais; Pinto-Medel, María Jesús; Guerrero, Miguel; León, Antonio; López-Madrona, José Carlos; Maldonado-Sánchez, Rafael; García-León, Juan Antonio; Luque, Gloria; Fernández, Victoria; Leyva-Fernández, Laura[et al.] (SAGE, 2011-03)
Natalizumab is a monoclonal antibody shown to be highly effective in the treatment of relapsing-remitting multiple sclerosis (RRMS). Patients treated with natalizumab can develop antibodies directed against this agent that ...